J. Gibbs

G. Prendergast, R. Diehl, A. Kral, 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.

T. Ciccarone, A. Kral, J. Davide, 1996, Journal of medicinal chemistry.

Role of GTPase activating protein in mitogenic signalling through phosphatidylcholine‐hydrolysing phospholipase C.

F. McCormick, M. Diaz-Meco, J. Moscat, 1991, The EMBO journal.

src-homology 2 (SH2) domain ligation as an allosteric regulator: modulation of phosphoinositide-specific phospholipase C gamma 1 structure and activity.

J. Gibbs, D. Pompliano, G. Edwards, 1995, Biochemical Journal.

The ras Oncogene Protein

R. Dixon, E. Scolnick, I. Sigal, 1989 .

Isolation and structure of chaetomellic acids A and B from Chaetomella acutiseta: farnesyl pyrophosphate mimic inhibitors of ras farnesyl-protein transferase

J. Gibbs, R. Mosley, K. Silverman, 1993 .

Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase.

N. Kohl, R. Lobell, J. Gibbs, 1999, Bioorganic & medicinal chemistry letters.

Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.

N. Kohl, J. Gibbs, E. Rands, 1999, Journal of medicinal chemistry.

Chemistry and Biology of Cylindrols: Novel Inhibitors of Ras Farnesyl-Protein Transferase from Cylindrocarpon lucidum.

J. Gibbs, K. Silverman, G. Bills, 1996, The Journal of organic chemistry.

Purification of ras GTPase activating protein from bovine brain.

J B Gibbs, E. Scolnick, I. Sigal, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Dissociation of RNA synthesis from the calcium requirement for serum-increased ornithine decarboxylase activity in rat glioma cells.

G. Brooker, J. Gibbs, 1984, Biochimica et biophysica acta.

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

N. Rosen, N. Kohl, L. Sepp-Lorenzino, 1995, Cancer research.

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

N. Kohl, J. Gibbs, A. Oliff, 1994, Cell.

Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.

N. Kohl, J. Gibbs, S. Graham, 1998, Journal of medicinal chemistry.

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.

J. Gibbs, A. Oliff, Jackson B. Gibbs, 1997, Annual review of pharmacology and toxicology.

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

G. Prendergast, J. Davide, N. Kohl, 1994, Molecular and cellular biology.

Modulation of guanine nucleotides bound to Ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP).

J B Gibbs, R. Dixon, E. Scolnick, 1990, The Journal of biological chemistry.

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

A. Kral, J. Davide, N. Kohl, 1995, Nature Medicine.

Cloning of bovine GAP and its interaction with oncogenic ras p21

Irving S. Sigal, R. Dixon, E. Scolnick, 1988, Nature.

CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae.

L. C. Robinson, I. Sigal, M. Marshall, 1987, Science.

Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

J B Gibbs, E. Scolnick, I. Sigal, 1984, Proceedings of the National Academy of Sciences of the United States of America.

S. cerevisiae genes IRA1 and IRA2 encode proteins that may be functionally equivalent to mammalian ras GTPase activating protein

M. Nakafuku, Kunihiro Matsumoto, M. Marshall, 1990, Cell.

A C‐terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity.

R. Dixon, E. Scolnick, I. Sigal, 1989, The EMBO journal.

PDGF induction of tyrosine phosphorylation of GTPase activating protein

T. Fleming, S. Aaronson, C. Molloy, 1989, Nature.

Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS1

R. Muschel, D. Kusewitt, S. Sebti, 2000, Radiation research.

Selection of Potent Inhibitors of Farnesyl-protein Transferase from a Synthetic Tetrapeptide Combinatorial Library*

R. Cortese, J. Gibbs, A. Pessi, 1996, The Journal of Biological Chemistry.

Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/“effector” domain

D. Stacey, M. Marshall, J. Gibbs, 1991, Cell.

The ras oncogene--an important regulatory element in lower eucaryotic organisms

M. Marshall, J. Gibbs, 1989, Microbiological reviews.

Purification and Molecular Cloning of Bovine GAP

R. Dixon, E. Scolnick, I. Sigal, 1989 .

Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21.

E. Scolnick, I. Sigal, J. Gibbs, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

N. Kohl, J. Gibbs, H. Hatch, 2007, Cancer research.

Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effects.

E. Scolnick, I. Sigal, J. Gibbs, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Ras regulatory interactions: Novel targets for anti‐cancer intervention?

G. Prendergast, J. Gibbs, 1994, BioEssays : news and reviews in molecular, cellular and developmental biology.

Ras C-terminal processing enzymes—New drug targets?

J. Gibbs, 1991, Cell.

Anticancer drug targets: growth factors and growth factor signaling.

J B Gibbs, J. Gibbs, 2000, The Journal of clinical investigation.

Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases.

C. M. Allen, G. Prendergast, S. Powers, 1993, Biochemistry.

Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras

J B Gibbs, D. Stacey, J. Gibbs, 1991, Molecular and cellular biology.

Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts

Yi Tang, J. Field, J. Chernoff, 1997, Molecular and cellular biology.

Inhibition of the ras p21 GTPase-activating protein-stimulated GTPase activity of c-Ha-ras p21 by smg p21 having the same putative effector domain as ras p21s.

T. Sasaki, Y. Hata, J. Gibbs, 1990, The Journal of biological chemistry.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

C. Paweletz, K. Kunii, I. Kariv, 2010, Cancer research.

A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis

D. Troyer, M. Subler, J. Windle, 1998, Molecular and Cellular Biology.

Determination of Ras and GTPase-activating protein interactions by kinetic competition assay.

J. Gibbs, M. Schaber, 1995, Methods in enzymology.

Structure/function studies of the ras protein.

J B Gibbs, E. Scolnick, I. Sigal, 1988, Cold Spring Harbor symposia on quantitative biology.

Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes.

R. Storer, M. O. Bradley, J. Gibbs, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Resolution of a low molecular weight G protein in neutrophil cytosol required for NADPH oxidase activation and reconstitution by recombinant Krev-1 protein.

E. Eklund, J. Gibbs, C. Crean, 1991, The Journal of biological chemistry.

Molecular Biology of GAP and its Interaction with Oncogenic ras p21

R. Dixon, E. Scolnick, I. Sigal, 1989 .

Pharmaceutical research in molecular oncology

J. Gibbs, A. Oliff, 1994, Cell.

Sequence dependence of protein isoprenylation.

S. Moores, V. Garsky, M. Marshall, 1991, The Journal of biological chemistry.

Determination of guanine nucleotides bound to Ras in mammalian cells.

J. Gibbs, 1995, Methods in enzymology.

Ras interaction with the GTPase‐activating protein (GAP)

E. Scolnick, V. Garsky, I. Sigal, 1989, Proteins.

Generation and screening of solution-phase synthetic peptide combinatorial libraries

R. Cortese, J. Gibbs, A. Pessi, 1999 .

N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.

N. Kohl, J. Gibbs, E. Rands, 1998, Journal of Medicinal Chemistry.

Reconstitution of interactions between the Src tyrosine kinases and Ras GTPase-activating protein using a baculovirus expression system.

R. Jove, M. Marshall, J. Gibbs, 1992, The Journal of biological chemistry.

Calcium and microtubule dependence for increased ornithine decarboxylase activity stimulated by beta-adrenergic agonists, dibutyryl cyclic AMP, or serum in a rat astrocytoma cell line.

G. Brooker, J. Gibbs, W. L. Terasaki, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.

N. Kohl, J. Gibbs, S. Graham, 1996, Biochemical Society transactions.

Identification of guanine nucleotides bound to ras-encoded proteins in growing yeast cells.

E. Scolnick, I. Sigal, M. Marshall, 1987, The Journal of biological chemistry.

New molecular targets for cancer therapy.

F. McCormick, J. Gibbs, A. Oliff, 1996, Scientific American.

Calcium and calmodulin activation of muscle phosphorylase kinase

A. Depaoli-Roach, P. Roach, J. Gibbs, 1979, FEBS Letters.

The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.

J. Davide, R. Lobell, J. Gibbs, 2002, Bioorganic & medicinal chemistry letters.

Calcium dependence for increased antizyme inhibitory activity of ornithine decarboxylase in rat glioma cells.

G. Brooker, J. Gibbs, 1984, Biochimica et biophysica acta.

Identification of amino acid residues required for Ras p21 target activation

E. Scolnick, L. Davis, M. Marshall, 1991, Molecular and cellular biology.

Reconstitution of p21ras-dependent and -independent mitogen-activated protein kinase activation in a cell-free system.

J. Maller, J. Gibbs, B. Vanrenterghem, 1993, The Journal of biological chemistry.

Anticancer drug targets: growth factors and growth factor signaling.

J. Gibbs, 2000, The Journal of clinical investigation.

Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back

Alcino J. Silva, G. Nolan, A. Balmain, 2010, American journal of medical genetics. Part A.

Effect of chlorambucil and indomethacin on growth and prostaglandin levels in sensitive and resistant Walker carcinoma.

J. Gibbs, M. Tisdale, R. Dobrzanski, 1982, Chemico-biological interactions.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

C. Paweletz, K. Kunii, I. Kariv, 2010, Cancer research.